ITK与RLK抑制剂PRN694在两种银屑病小鼠模型中改善皮肤病变
该研究评估小分子PRN694共价结合ITK与RLK两种Tec激酶对银屑病的作用。体外实验显示PRN694有效抑制小鼠Th17分化T淋巴细胞的IL-17A产生;在Rac1V12与咪喹莫特两种银屑病小鼠模型中,PRN694减轻银屑病样表型严重程度,减少表皮增殖与厚度,并抑制CD3+ T细胞与γδ T细胞浸润皮肤。
要点
- PRN694共价结合ITK与RLK,二者在银屑病皮肤中上调。
- PRN694体外抑制小鼠Th17细胞IL-17A产生。
- 两种小鼠模型中PRN694减轻银屑病样表型并减少T细胞皮肤浸润。
核心结论
- PRN694抑制ITK与RLK可减弱银屑病相关信号通路,是有效的银屑病治疗候选。
- PRN694在两种银屑病小鼠模型中减轻银屑病样表型严重程度。
研究设计与样本
- 研究为小鼠模型与体外实验,采用Rac1V12和咪喹莫特两种银屑病小鼠模型。
- 体外分析使用小鼠Th17分化T淋巴细胞评估PRN694对IL-17A产生的影响。
主要发现
- PRN694有效抑制小鼠Th17分化T淋巴细胞的IL-17A产生。
- PRN694减轻Rac1V12与咪喹莫特小鼠模型的银屑病样表型严重程度。
- PRN694减少两种模型中的表皮增殖与表皮厚度。
- PRN694抑制CD3+ T细胞与γδ T细胞浸润至皮肤区域。
- 抑制ITK与RLK减弱了银屑病相关信号通路。
临床怎么用
- PRN694靶向Tec激酶ITK与RLK,为银屑病治疗提供小分子候选方向。
- 其作用涉及抑制IL-17A产生及减少T细胞皮肤浸润。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The chronic and highly prevalent skin disorder psoriasis vulgaris is characterized by a hyperproliferative epidermis and aberrant immune activity. Many studies have highlighted the role of differentiated T lymphocytes in psoriasis progression. Several biologics are currently available that target proinflammatory cytokines produced by T lymphocytes, but the need for improved therapies persists. The small molecule PRN694 covalently binds ITK and RLK, two Tec kinases activated downstream of T-lymphocyte activation, both of which are up-regulated in psoriatic skin. These Tec kinases are involved in signaling cascades mediating T-lymphocyte proliferation, differentiation, and migration and proinflammatory cytokine production. In vitro analysis showed that PRN694 effectively inhibited IL-17A production from murine T helper type 17-differentiated T lymphocytes. Additionally, PRN694 effectively reduced the psoriasis-like phenotype severity and reduced epidermal proliferation and thickness in both the Rac1V12 and imiquimod mouse models of psoriasis. PRN694 also inhibited CD3+ T-cell and γδ T-cell infiltration into skin regions. Inhibition of ITK and RLK attenuated psoriasis-associated signaling pathways, indicating that PRN694 is an effective psoriasis therapeutic.
引用
- Fuhriman JM, Winge MCG, Haberstock-Debic H, et al. ITK and RLK Inhibitor PRN694 Improves Skin Disease in Two Mouse Models of Psoriasis. J Invest Dermatol. 2017. PMID: 29129599. doi:10.1016/j.jid.2017.10.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。